Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2003 1
2005 6
2006 3
2007 1
2009 9
2010 7
2011 1
2012 3
2013 8
2014 12
2015 12
2016 18
2017 10
2018 8
2019 11
2020 11
2021 6
2022 8
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
Fehniger TA, Watkins MP, Ezenwajiaku N, Wan F, Hurd DD, Cashen AF, Blum KA, Goy A, Fenske TS, Wagner-Johnston ND, Carson K, Siegel MJ, Russler-Germain D, Schneider SE, Mehta-Shah N, Kahl B, Bartlett NL. Fehniger TA, et al. Among authors: carson k. Haematologica. 2024 Mar 1;109(3):953-957. doi: 10.3324/haematol.2022.282246. Haematologica. 2024. PMID: 37706336 Free PMC article. Clinical Trial. No abstract available.
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.
Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, Knoche EM, Whitmer AL, Yan Y, Drake BF, Sanfilippo KM. Schoen MW, et al. Among authors: carson kr. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):811. doi: 10.1038/s41391-023-00680-4. Prostate Cancer Prostatic Dis. 2023. PMID: 37253974 Free PMC article. No abstract available.
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.
Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, Knoche EM, Whitmer AL, Yan Y, Drake BF, Sanfilippo KM. Schoen MW, et al. Among authors: carson kr. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):743-750. doi: 10.1038/s41391-022-00588-5. Epub 2022 Sep 14. Prostate Cancer Prostatic Dis. 2023. PMID: 36104504 Free PMC article.
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project.
Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NPC, Pileri SA, Montoto S, Horwitz SM, Cabrera ME, De Souza CA, Nagler A, Luminari S, Ferreri AJM, Carson KR, Re A, Rigacci L, Nassi L, Stepanishyna Y, Federico M, Inghirami G. Chiattone C, et al. Among authors: carson kr. Hematol Oncol. 2022 Dec;40(5):953-961. doi: 10.1002/hon.3074. Epub 2022 Sep 15. Hematol Oncol. 2022. PMID: 36083035
117 results